Australia markets closed

4D pharma plc (LBPS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.12-0.22 (-3.00%)
At close: 4:00PM EDT

4D pharma plc

9 Bond Court
5th Floor
Leeds LS1 2JZ
United Kingdom
44 11 3895 0130

Full-time employees92

Key executives

NameTitlePayExercisedYear born
Mr. Duncan Joseph PeytonCEO & Exec. Director139.94kN/A1970
Dr. Alexander James Stevenson Ph.D.Chief Scientific Officer & Exec. Director139.94kN/A1972
Mr. Glenn DouradoChief Bus. OfficerN/AN/AN/A
Mr. Richard AvisonVP of Fin.N/AN/A1978
Ms. Fay WestonHead of Investor RelationsN/AN/AN/A
Mr. Adrian MurrayGen. Counsel (Interim)N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Corporate governance

4D pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.